

Product datasheet for **TR303640**

Kallikrein 15 (KLK15) Human shRNA Plasmid Kit (Locus ID 55554)

Product data:

Product Type:	shRNA Plasmids
Product Name:	Kallikrein 15 (KLK15) Human shRNA Plasmid Kit (Locus ID 55554)
Locus ID:	55554
Synonyms:	ACO; HSRNASPH
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	KLK15 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 55554). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	NM_001277081 , NM_001277082 , NM_017509 , NM_023006 , NM_138563 , NM_138564 , NR_102274 , NM_017509.1 , NM_017509.2 , NM_017509.3 , NM_138564.1 , NM_138563.1 , NM_001277082.1 , NM_001277081.1 , NM_023006.1 , BC069507 , BC069507.1 , BC069480 , BC069518 , BC126137 , BC144045 , BC144046 , BC144047
UniProt ID:	Q9H2R5
Summary:	Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. In prostate cancer, this gene has increased expression, which indicates its possible use as a diagnostic or prognostic marker for prostate cancer. The gene contains multiple polyadenylation sites and alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).